As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ...

For individuals living with type 2 diabetes or struggling with weight loss, Rybelsus has become a popular name in the realm of oral GLP-1 receptor agonists. While its effectiveness in lowering blood ...

WEIGHT loss injections have become the holy grail in the fight against obesity, helping people shift the pounds they’ve been ...

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

Sam Peasah, PhD, MBA, RPh, director of High-Value Health Care Value-Based Pharmacy Initiatives at UPMC Health Plan, discusses ways that health plans can help reduce the cost burden of medications to ...

A new study has found that 10-hydroxy-cis-12-octadecenoic acid (HYA), a metabolite derived from linoleic acid by gut microbiota, can help reduce ...

My dad, Michael Mosley, was an inspiration to millions of people worldwide – particularly those living with obesity or type 2 ...

The Cambridgeshire, England-based biopharmaceutical company reported a pretax loss of GBP10.6 million in 2024, widened from GBP8.9 million in 2023. Revenue was GBP5.1 million, up 10% from GBP4.6 ...

Popular prescription weight-loss drugs called GLP-1 receptor agonists are now frequently used by type 1 diabetes patients, ...